Articles related to DYSLIPIDEMIA

Synthetic DNA molecules known as polypurine reverse Hoogsteen hairpins reduced PCSK9 expression and lowered LDL cholesterol by approximately 50% in preclinical models, representing an early-stage gene-targeted approach distinct from existing monoclonal antibody and RNA interference strategies.

Lerochol (lerodalcibep-liga), a once-monthly self-administered PCSK9 inhibitor, is now commercially available as adjunctive LDL-C-lowering therapy for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

ACC/AHA’s 2026 dyslipidemia guideline reintroduces LDL-C and non-HDL-C treatment goals, replaces Pooled Cohort Equations with PREVENT, and recommends one-time lipoprotein(a) measurement in all adults.

According to the Gould Registry, in 5,006 patients with ASCVD, only one in three patients had LDL cholesterol even less than 70mg/dl.

“People who maintain low levels of LDL-C and triglycerides at earlier ages are much less likely to develop atherosclerotic disease decades later.” — Pamela B. Morris, MD, FACC, FAHA, guideline writing committee vice-chair

Fixed-dose combination achieved 71% target LDL attainment versus 25% with ezetimibe alone in high-risk cardiovascular patients.